Price Target Update on Celgene Corporation (NASDAQ:CELG)

Celgene Corporation (NASDAQ:CELG) stock is expected to deviate a maximum of $13.97 from the average target price of $142.5 for the short term period. 14 Street Experts have initiated coverage on the stock with the most promising target being $162 and the most muted being $120.

Other Equity analysts have also commented on the company shares. Major Brokerage house, BTIG Research downgrades its ratings on Celgene Corporation (NASDAQ:CELG). According to the latest information available, the shares are now rated Neutral by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on June 1, 2016.

Celgene Corporation (NASDAQ:CELG): stock turned positive on Thursday. Though the stock opened at $100.26, the bulls momentum made the stock top out at $100.76 level for the day. The stock recorded a low of $99.25 and closed the trading day at $100.66, in the green by 1.44%. The total traded volume for the day was 3,831,469. The stock had closed at $99.23 in the previous days trading.

The company shares have dropped -16.48% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $140.72 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $102.61 and the 200 Day Moving Average price is recorded at $104.93. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Kaplan Gilla, director of Celgene Corp /De/, had unloaded 15,967 shares at an average price of $101.84 in a transaction dated on April 4, 2016. The total value of the transaction was worth $1,626,079.

Celgene Corporation (Celgene), together with its subsidiaries, is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE, POMALYST/IMNOVID, VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States), OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies, targeting areas, including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.